Update on nonsurgical therapy for diabetic macular edema

Current Opinion in Ophthalmology

Volumn 22, Issue 3, 2011, Pages 185-189

  Witkin, Andre J ^a   Brown, Gary C ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

bevacizumab; corticosteroids; diabetic macular edema; diabetic retinopathy; ranibizumab

Indexed keywords

AGENTS ACTING ON THE EYE; BEVACIZUMAB; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; ILUVIEN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ARTICLE; CATARACT EXTRACTION; COMPARATIVE STUDY; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG TARGETING; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955073933     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283459724     Document Type: Article

References (41)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
2. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema: ETDRS report no. 4. Int Ophthalmol Clin 1987; 27:265-272
3. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for DME: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985; 103:1796-1806.
4. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114:525-536.
5. Early Treatment Diabetic Retinopathy Study Research Group R. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995 113:1144-1155.
6. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98:1594-1602.
7. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001; 79:435-440. (Pubitemid 32962830)
8. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115:64-67. (Pubitemid 23019040)
9. Wilson DJ, Finkelstein D, Quigley HA, Green RW. Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol 1988; 106:100-105. (Pubitemid 18028650)
10. Bresnik GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983; 90:1301-1317.
11. Rutledge BK, Wallow IH, Poulsen GL. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol 1993; 111:608-613. (Pubitemid 23143164)
12. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109:1549-1555.
13. Jain A, Collen J, Kaines A, et al. Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes. Retina 2010; 30:1622-1626.
14. Sivaprasad S, Elagouz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 2010; 55:516-530.
15. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007:95103.
16. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341:309-315. (Pubitemid 28131129)
17. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007; 39:1-12.
18. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132:425-427. (Pubitemid 32768624)
19. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927. (Pubitemid 34465226)
20. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111:218-224. (Pubitemid 38183217)
21. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113:1533-1538. (Pubitemid 44292310)
22. Chew E, Strauber S, Beck R, et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007; 114:1190-1196.
23. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447-1449.
24. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007; 114:2162-2167.
25. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140:695-702.
26. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124:653-658.
27. Diabetic Retinopathy Clinical Research Network, [583 collaborators]. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 117 2010:1064-1077
28. Pearson A, Levy B, The Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treatDME: 2-year results of a multicenter clinical trial. Invest Ophthalmol Vis Sci 2005; 46:; E-Abstract 1795.
29. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117:1393-1399.
30. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
31. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27:331-371.
32. Murugeswari P, Shukla D, Rajendran A, et al. Proinflammatory cytokines and angiogenic and antiangiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales' disease. Retina 2008; 28:817-824.
33. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108:2369-2379.
34. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
35. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487. (Pubitemid 24356306)
36. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized doublemasked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747-1757.
37. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
38. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078-1086.
39. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116:2175-2181.
40. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117:2146-2151.
41. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33:2399-2405.